NCT06692452 2026-04-01Tazemetostat Plus CHOP in 1L T-cell LymphomaDana-Farber Cancer InstitutePhase 2 Withdrawn
NCT03999658 2023-05-01A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory MalignanciesSorrento Therapeutics, Inc.Phase 2 Withdrawn
NCT05239910 2022-10-17Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCLRhizen Pharmaceuticals SAPhase 2 Withdrawn
NCT01652014 2016-07-14Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic MalignanciesRutgers, The State University of New JerseyPhase 2 Withdrawn